

BIOTECanada announces appointments to Board of Directors for 2009-10

Ottawa (May 7, 2009) – The national biotechnology association, BIOTECanada, announced their 2009-2010 Board of Directors, as appointed during the Annual General Meeting held on Friday May 1, 2009 in Toronto, Ontario.

"The association is pleased to welcome these knowledgeable leaders with recognized experience in the industry to our board as part of the normal cycle of board membership," said incoming Chair of the Board, Brad Thompson, President & CEO, Oncolytics Biotech Inc. "We would also like to thank those retiring members for their service and dedication to the industry. BIOTECanada's volunteer Board of Directors is an active group with expertise across all sectors of biotechnology and its members represent both small and large biotechnology companies in Canada.

"Roche Canada has been a strong supporter of BIOTECanada for several years as the healthcare system has increasingly relied on biologic technology to care for patients," said Ronnie Miller, President & CEO, Roche Canada. "The association is an essential player in the development and growth of our industry and I look forward to improving collaboration between the life sciences and pharmaceutical sectors. Our combined strengths will help ensure we have one formidable voice with policy makers as they shape the future of healthcare in this country."

"The Board of Directors is embarking on valuable initiatives for 2009 that I'm pleased to be a part of. This is an important time for biotech and I look forward to working with the board and association members as we develop Canada's plan to lead the bio-based economy," said Thomas Bailey, CFO of Angiotech Pharmaceuticals Inc.

"The network of almost 250 member companies leading the Canadian biotechnology industry is vital to our advocacy and public awareness efforts aimed at increasing our capacity to compete and lead in the international marketplace," said Brian Lewis, General Manager of Genzyme Canada Ltd.

-30-

Contact: Kasia Majewski
Tel: 613-230 5585 x 257
Cell: 613 219 2770
kasia.majewski@biotech.ca

ABOUT BIOTECanada www.biotech.ca

BIOTECanada is dedicated to the sustainable commercial development of biotechnology innovation in Canada. It is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations.



2009- 2010 BIOTECanada Board of Directors

Brad Thompson, President & CEO, Oncolytics Biotech Inc. (Chair)

Rainer Engelhardt, CEO, Eulytica (Past-Chair)

Yves Rosconi, President & CEO, Theratechnologies Inc. (Vice-Chair)

René Douville, Director, RBC Capital Markets (Treasurer)

Peter Matthewman, President & CEO, Performance Plants (Member at Large)

Peter Brenders, President & CEO, BIOTECanada

Thomas Bailey, CFO, Angiotech Pharmaceuticals Inc.

Alain Beaudet, President, CIHR

Randal Chase, President & CEO, ImmunoVaccine Technologies

Jane Clark, Life Sciences Group Leader, Gowling Lafleur Henderson LLP

Richard Francis, President & General Manager, Biogen Idec Canada Inc.

John Langstaff, President & CEO, Cangene Corporation

Paul Levesque, President & CEO, Pfizer Canada Inc.

Brian Lewis, General Manager, Genzyme Canada

Ross MacLachlan, President & CEO, Lignol Energy Corporation

Luc Mainville, President & CEO, LAB Research Inc.

Gordon McCauley, President & CEO, Allon Therapeutics, Inc.

Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance

Ronnie Miller, President & CEO, Hoffmann-La Roche Limited

Andrew Sheldon, President & CEO, Medicago Inc.

Jim Wispinski, President & CEO, Dow AgroSciences Canada Inc.

